US Patent

US10548904 — Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof

Method of Use · Assigned to Ferring BV · Expires 2029-02-03 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects monolithic intravaginal rings containing progesterone, a method of making them, and their uses.

USPTO Abstract

The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.

Drugs covered by this patent

Endometrin (progesterone) · Ferring

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2810`	—	Endometrin

Patent Metadata

Patent number: US10548904
Jurisdiction: US
Classification: Method of Use
Expires: 2029-02-03
Drug substance claim: No
Drug product claim: No
Assignee: Ferring BV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.